It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
High quality, well-validated antibodies are needed to mitigate irreproducibility and clarify conflicting data in science. We describe an epitope-directed monoclonal antibody (mAb) production method that addresses issues of antibody quality, validation and utility. The workflow is illustrated by generating mAbs against multiple in silico-predicted epitopes on human ankyrin repeat domain 1 (hANKRD1) in a single hybridoma production cycle. Antigenic peptides (13–24 residues long) presented as three-copy inserts on the surface exposed loop of a thioredoxin carrier produced high affinity mAbs that are reactive to native and denatured hANKRD1. ELISA assay miniaturization afforded by novel DEXT microplates allowed rapid hybridoma screening with concomitant epitope identification. Antibodies against spatially distant sites on hANKRD1 facilitated validation schemes applicable to two-site ELISA, western blotting and immunocytochemistry. The use of short antigenic peptides of known sequence facilitated direct epitope mapping crucial for antibody characterization. This robust method motivates its ready adoption for other protein targets.
Liew et al. describe an efficient monoclonal antibody (mAb) production method and as a proof-of-concept, develop mAbs against multiple epitopes on hANKRD1 in a single hybridoma production cycle. With rapid screening and validation techniques, this pipeline shows promise of general applicability for antibody panel generation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
2 National University of Singapore, Department of Biological Sciences, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
3 Laboratory for Optics & Applied Mechanics, Department of Mechanical & Aerospace Engineering, Monash University, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
4 Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); University of Otago, Christchurch Heart Institute, Christchurch, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830)